CR20180042A - Unidad de dosificación orodispersable que contiene un componente estetrol. - Google Patents

Unidad de dosificación orodispersable que contiene un componente estetrol.

Info

Publication number
CR20180042A
CR20180042A CR20180042A CR20180042A CR20180042A CR 20180042 A CR20180042 A CR 20180042A CR 20180042 A CR20180042 A CR 20180042A CR 20180042 A CR20180042 A CR 20180042A CR 20180042 A CR20180042 A CR 20180042A
Authority
CR
Costa Rica
Prior art keywords
dosage unit
estetrol
weight
component
solid dosage
Prior art date
Application number
CR20180042A
Other languages
English (en)
Inventor
Johannes Jan; Platteeuw
Den Heuvel Denny Johan Marijn; Van
Séverine Francine Isabelle; Jaspart
Original Assignee
Mithra Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mithra Pharmaceuticals S A filed Critical Mithra Pharmaceuticals S A
Publication of CR20180042A publication Critical patent/CR20180042A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona una unidad de dosificación sólida orodispersable farmacéutica que tiene un peso comprendido entre 30 y 1.000 mg, consistiendo dicha unidad de dosificación en: ¿ 0,1-25 % en peso de partículas de estetrol que contienen al menos 80 % en peso de un componente estetrol seleccionado entre estetrol, ésteres de estetrol y combinaciones de los mismos; y ¿ 75-99,9 % en peso de uno o más ingredientes farmacéuticamente aceptables; comprendiendo la unidad de dosificación sólida al menos 100 µg del componente estetrol; y en la que la unidad de dosificación sólida se puede obtener mediante un procedimiento que comprende la compresión de una mezcla seca de partículas de estetrol y uno o más excipientes farmacéuticamente aceptables en una unidad de dosificación sólida. La unidad de dosificación sólida es fácil de fabricar y perfectamente adecuada para su administración sublingual, bucal o sublabial.
CR20180042A 2015-06-18 2016-06-17 Unidad de dosificación orodispersable que contiene un componente estetrol. CR20180042A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15172747 2015-06-18
PCT/EP2016/064074 WO2016203011A1 (en) 2015-06-18 2016-06-17 Orodispersible dosage unit containing an estetrol component

Publications (1)

Publication Number Publication Date
CR20180042A true CR20180042A (es) 2018-05-03

Family

ID=53442623

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180042A CR20180042A (es) 2015-06-18 2016-06-17 Unidad de dosificación orodispersable que contiene un componente estetrol.

Country Status (43)

Country Link
US (3) US20160367567A1 (es)
EP (1) EP3106148B1 (es)
JP (1) JP6863547B2 (es)
KR (1) KR102664563B1 (es)
CN (2) CN116077454A (es)
AU (1) AU2016280863B2 (es)
CA (1) CA2988498C (es)
CL (1) CL2017003208A1 (es)
CO (1) CO2017012766A2 (es)
CR (1) CR20180042A (es)
CU (1) CU24523B1 (es)
CY (1) CY1120467T1 (es)
DK (1) DK3106148T3 (es)
DO (1) DOP2017000293A (es)
EA (1) EA035651B1 (es)
EC (1) ECSP17085669A (es)
ES (1) ES2671160T3 (es)
GE (2) GEAP202114677A (es)
GT (1) GT201700270A (es)
HK (1) HK1251940A1 (es)
HR (1) HRP20180889T1 (es)
HU (1) HUE037383T2 (es)
IL (1) IL256283B (es)
LT (1) LT3106148T (es)
MX (1) MX385820B (es)
MY (1) MY195019A (es)
NO (1) NO3106148T3 (es)
NZ (1) NZ737948A (es)
PE (1) PE20180398A1 (es)
PH (1) PH12017502325B1 (es)
PL (1) PL3106148T3 (es)
PT (1) PT3106148T (es)
RS (1) RS57328B1 (es)
SA (1) SA517390550B1 (es)
SG (1) SG10202010432UA (es)
SI (1) SI3106148T1 (es)
SM (1) SMT201800232T1 (es)
SV (1) SV2017005595A (es)
TN (1) TN2017000499A1 (es)
TR (1) TR201808438T4 (es)
UA (1) UA123098C2 (es)
WO (1) WO2016203011A1 (es)
ZA (1) ZA201708287B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012164096A1 (en) 2011-06-01 2012-12-06 Estetra S.A. Process for the production of estetrol intermediates
BR112013030833B1 (pt) 2011-06-01 2019-09-03 Estetra S A processo para a preparação de um composto de fórmula (i) e processo para a preparação de estetrol
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
RS57328B1 (sr) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu
WO2016203044A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
NZ737945A (en) * 2015-06-18 2023-06-30 Estetra Sprl Orodispersible dosage unit containing an estetrol component
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CR20200486A (es) * 2018-04-19 2021-01-27 Estetra Sprl Compuestos y sus usos para aliviar los síntomas asociados a la menopausa
TWI801561B (zh) * 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
AU2021351921A1 (en) 2020-09-29 2023-04-06 Millicent Pharma Limited Orodispersible formulations

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
CA1306950C (en) 1987-04-10 1992-09-01 Alec D. Keith Buccal administration of estrogens
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
CA2011063C (en) 1989-02-28 1999-07-06 Calum B. Macfarlane Nicardipine pharmaceutical composition for parenteral administration
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
BR9813808A (pt) 1997-12-19 2002-05-28 Smithkline Beecham Corp Processo para produção de comprimidos para dispersão na mordida
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6180682B1 (en) * 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
US6706700B2 (en) 1999-12-02 2004-03-16 Akzo-Nobel, N.V. 14β,15β-methylene-17α-hydroxymethyl-androgens
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
DE60217324T2 (de) * 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
US7732430B2 (en) 2001-05-23 2010-06-08 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
ATE254465T1 (de) * 2001-05-23 2003-12-15 Pantarhei Bioscience Bv Zubereitungen für die hormonale kontrazeption
US20020193356A1 (en) 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
EP1390041B1 (en) 2001-05-23 2009-11-25 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
ATE347365T1 (de) 2001-11-15 2006-12-15 Pantarhei Bioscience Bv Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
CA2476940C (en) 2002-02-21 2011-11-01 Bayer Intellectual Property Gmbh Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
AU2003274946A1 (en) 2002-06-11 2003-12-22 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
CA2489270C (en) 2002-06-11 2012-08-07 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
US9034854B2 (en) 2002-07-12 2015-05-19 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
MXPA05002294A (es) 2002-08-28 2005-09-12 Casper Robert Regimen de sustitucion de estrogeno.
US8987240B2 (en) 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
ES2338781T3 (es) 2002-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Uso de la drospirenona para el tratamiento de una hipertension.
AU2003279624A1 (en) 2002-11-08 2004-06-07 Pantarhei Bioscience B.V. Synthesis of estetrol via estrone derived steroids
DK1624878T3 (da) 2003-05-22 2007-01-08 Pantarhei Bioscience Bv Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte
EP2409690B1 (en) 2003-09-29 2022-11-09 Novo Nordisk Health Care AG Improved stability of progestogen formulations
PL1670440T3 (pl) 2003-09-29 2014-11-28 Novo Nordisk Healthcare Ag Preparaty HRT
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
PT1755562E (pt) 2004-05-28 2013-12-26 Richter Gedeon Nyrt Contraceptivo contendo ácido fólico
EA013211B1 (ru) 2004-07-01 2010-04-30 Лек Фармасьютиклз Д.Д. Быстрораспадающаяся диспергирующаяся во рту лекарственная форма и способ ее приготовления
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
EA013867B1 (ru) 2005-02-03 2010-08-30 Никомед Фарма Ас Способ получения гранулята, содержащего карбонат кальция
IS7724A (is) 2005-03-02 2006-09-03 Actavis Group Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
EP1888615B1 (en) 2005-05-26 2012-05-16 Abbott Products GmbH 17 -hsd1 and sts inhibitors
US20070048369A1 (en) * 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
EP1971344B1 (en) 2006-01-09 2010-09-22 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
CN101378762A (zh) * 2006-01-09 2009-03-04 潘塔希生物科学股份有限公司 一种治疗急性血管疾病的方法
ES2558030T3 (es) 2006-03-02 2016-02-01 Warner Chilcott Company, Llc Método anticonceptivo oral multifásico de ciclo prolongado
ES2659316T3 (es) 2006-06-08 2018-03-14 Allergan Pharmaceuticals International Limited Procedimientos para administrar formas de dosificación sólidas de etinilestradiol y profármacos del mismo con biodisponibilidad mejorada
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
US20070286819A1 (en) * 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
DE112007001600A5 (de) 2006-07-06 2009-04-30 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
CN101541326A (zh) 2006-11-29 2009-09-23 惠氏公司 雌激素/选择性雌激素受体调节剂（serm）和雌激素/孕酮双层药片
ES2531929T3 (es) 2006-12-20 2015-03-20 Teva Women's Health, Inc. Formas de dosificación solidas que se disgregan en la boca que comprenden progestina y métodos para hacer y usar las mismas
CN101583363B (zh) 2007-01-08 2013-08-21 潘塔希生物科学股份有限公司 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒
KR20090104862A (ko) 2007-01-12 2009-10-06 와이어쓰 정제내 정제 조성물
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
US8367647B2 (en) 2007-06-21 2013-02-05 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
WO2009011576A1 (en) 2007-07-19 2009-01-22 Pantarhei Bioscience B.V. Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation
FR2920311B1 (fr) 2007-08-31 2010-06-18 Galenix Innovations Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation
JP5399749B2 (ja) 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
US20110250274A1 (en) 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
CN101780073B (zh) 2009-01-21 2013-07-03 重庆圣华曦药业股份有限公司 非布司他分散片药物及其制备方法
JP5753661B2 (ja) 2009-01-26 2015-07-22 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース水分散液を用いた湿式造粒打錠法
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
JP2012521393A (ja) 2009-03-26 2012-09-13 ロイヤル カレッジ オブ サージェオンズ イン アイルランド 口腔内分散性錠剤
KR20120044307A (ko) 2009-06-23 2012-05-07 바이엘 파마 악티엔게젤샤프트 긴급 피임용 제약 조성물
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
MX356702B (es) 2010-04-15 2018-06-11 Bayer Ip Gmbh Formas de dosificación sólidas orales con dosis muy bajas para la hrt.
EP2399904A1 (en) 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012055840A1 (en) 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
MX365568B (es) 2010-12-02 2019-06-07 Adare Pharmaceuticals Inc Granulos de dispersion rapida, comprimidos de disolucion oral y metodos.
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
BR112013030833B1 (pt) 2011-06-01 2019-09-03 Estetra S A processo para a preparação de um composto de fórmula (i) e processo para a preparação de estetrol
WO2012164096A1 (en) 2011-06-01 2012-12-06 Estetra S.A. Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
HUE025350T2 (en) 2011-07-19 2016-02-29 Pantarhei Bioscience Bv Tablets containing dehydroepiandrosterone (DHEA)
BR112014003113A2 (pt) 2011-08-11 2017-03-14 Estetra Sprl método de contracepção de emergência em uma fêmea mamífero
BR112014005134A2 (pt) 2011-09-16 2017-04-18 Ferring Bv composição farmacêutica de dissolução rápida
EP2764008B1 (en) 2011-10-07 2016-08-17 Estetra S.P.R.L. Process for the production of estetrol
WO2013090117A1 (en) 2011-12-13 2013-06-20 Arstat, Inc. A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
US9238265B2 (en) 2012-09-27 2016-01-19 General Electric Company Backstrike protection during machining of cooling features
WO2014159377A1 (en) * 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
JP6126456B2 (ja) 2013-05-17 2017-05-10 東和薬品株式会社 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠
EP3943079A1 (en) 2013-05-21 2022-01-26 Predictive Therapeutics, LLC Therapeutic and method of use
EP3046928B1 (en) 2013-09-18 2017-02-08 Crystal Pharma, S.A.U. Process for the preparation of estetrol
US12274276B2 (en) 2013-10-03 2025-04-15 Altria Client Services Llc Dissolvable-chewable tablet
HUE035848T2 (en) 2013-12-12 2018-05-28 Donesta Bioscience B V Solid dispensing unit containing an estetrol compound in the mouth
ES2957543T3 (es) 2014-09-29 2024-01-22 Univ California Composiciones y métodos para mantener la función cognitiva
CA2986039A1 (en) 2015-05-18 2016-11-24 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects
RS57328B1 (sr) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu
WO2016203044A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
NZ737945A (en) 2015-06-18 2023-06-30 Estetra Sprl Orodispersible dosage unit containing an estetrol component
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
DK3313408T3 (da) 2015-06-23 2024-01-29 Laboratorios Leon Farma Sa Drospirenon-baseret svangerskabsforebyggende middel til en kvindelig patient, som lider af overvægt
CA3041016C (en) 2016-10-28 2023-09-05 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
US20200046729A1 (en) 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
UA126746C2 (uk) 2018-02-07 2023-01-18 Естетра Спрл Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи
CR20200486A (es) 2018-04-19 2021-01-27 Estetra Sprl Compuestos y sus usos para aliviar los síntomas asociados a la menopausa
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Also Published As

Publication number Publication date
CA2988498A1 (en) 2016-12-22
PL3106148T3 (pl) 2018-08-31
US11957694B2 (en) 2024-04-16
GEP20217308B (en) 2021-10-25
IL256283A (en) 2018-02-28
KR20180021085A (ko) 2018-02-28
US20160367567A1 (en) 2016-12-22
TR201808438T4 (tr) 2018-07-23
NO3106148T3 (es) 2018-08-11
LT3106148T (lt) 2018-06-25
MY195019A (en) 2023-01-03
CY1120467T1 (el) 2019-07-10
JP2018517717A (ja) 2018-07-05
DOP2017000293A (es) 2018-01-31
SI3106148T1 (en) 2018-08-31
MX2017016276A (es) 2018-06-19
US10660903B2 (en) 2020-05-26
ECSP17085669A (es) 2018-03-31
GT201700270A (es) 2019-08-30
HRP20180889T1 (hr) 2018-08-10
AU2016280863A1 (en) 2018-01-18
EA201890084A1 (ru) 2018-05-31
CU20170159A7 (es) 2018-07-05
NZ737948A (en) 2023-03-31
JP6863547B2 (ja) 2021-04-21
ES2671160T3 (es) 2018-06-05
KR102664563B1 (ko) 2024-05-09
RS57328B1 (sr) 2018-08-31
GEAP202114677A (en) 2021-06-10
US20190125759A1 (en) 2019-05-02
DK3106148T3 (en) 2018-05-07
TN2017000499A1 (en) 2019-04-12
HUE037383T2 (hu) 2018-08-28
SG10202010432UA (en) 2020-11-27
EA035651B1 (ru) 2020-07-22
WO2016203011A1 (en) 2016-12-22
CN116077454A (zh) 2023-05-09
SA517390550B1 (ar) 2022-03-16
CA2988498C (en) 2022-02-08
CU24523B1 (es) 2021-06-08
MX385820B (es) 2025-03-18
EP3106148B1 (en) 2018-03-14
PH12017502325B1 (en) 2021-04-14
EP3106148A1 (en) 2016-12-21
PH12017502325A1 (en) 2018-06-25
PE20180398A1 (es) 2018-02-28
IL256283B (en) 2021-02-28
CO2017012766A2 (es) 2018-03-28
PT3106148T (pt) 2018-05-10
ZA201708287B (en) 2020-01-29
CL2017003208A1 (es) 2018-04-13
SV2017005595A (es) 2018-09-10
UA123098C2 (uk) 2021-02-17
CN107771075A (zh) 2018-03-06
SMT201800232T1 (it) 2018-07-17
US20200352959A1 (en) 2020-11-12
AU2016280863B2 (en) 2021-04-01
HK1251940A1 (zh) 2019-05-03

Similar Documents

Publication Publication Date Title
CO2017012766A2 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
CO2017012670A2 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
CL2024000428A1 (es) Contra enfermedades inflamatorias intestinales que involucra la disrupción del ensamblaje de heterómeros ccr9:drd5
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla
CO2019013645A2 (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
EA201800226A1 (ru) Фармацевтическая композиция, обладающая анксиолитическим и снотворным действием
UA123399U (uk) Фармацевтична композиція холіну альфосцерату у лікарській формі для орального застосування
EA201691599A1 (ru) Комбинация таурина и рацеметионина для лечения заболеваний печени
AR094392A1 (es) Formulaciones de lorazepam de liberación controlada